GLPG1690 + itraconazole

GLPG1690 + itraconazole is a combination of two drugs used in a clinical research setting to study drug-drug interactions or pharmacokinetics. GLPG1690 is a novel, potent, oral small molecule inhibitor of autotaxin developed for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive scarring lung disease. Its mechanism involves inhibition of autotaxin, leading to reduced lysophosphatidic acid (LPA) levels, which play a role in lung fibrosis. Itraconazole is a marketed antifungal agent, commonly used for systemic and superficial fungal infections, and is a strong inhibitor of cytochrome P450 enzyme CYP3A4. The combination is not used as a therapy, but was studied in clinical trials to assess the pharmacokinetic interactions, such as potential changes in the absorption, metabolism, and elimination of GLPG1690 when co-administered with itraconazole in healthy subjects[1].